News
bioMérieux today announces that its BIOFIRE® SPOTFIRE® R/ST Panel Mini has received U.S. FDA 510(k) clearance and CLIA waiver for the addition of Anterior Nasal Swab as a validated specimen type for this panel.
Swipe to discover more
-
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. -
A new chapter in Quality Control – how USP Chapter <86> can transform approaches to endotoxin testing
Could 2025 be the year that endotoxin testing finally catches up with the 21st century? Unlike other areas of Pharmaceutical Quality Control where innovations such as data analytics and automation have driven extensive modernization, endotoxin testing has remained resolutely stuck in the past. This vital Quality Control procedure has until recently relied on outdated testing practices that require the blood of horseshoe crabs. Significantly, new authoritative standards have recently recognized alternative testing methods that can deliver the same important validation, without relying on animal-derived products. What are these new standards and what could their integration mean for the future of endotoxin testing? -
bioMérieux and Moderna Collaborate to Advance individualized Cancer Therapies
bioMérieux has a long history of collaboration with Moderna, a biotechnology company that gained worldwide recognition during the COVID-19 pandemic for its rapid development of a mRNA-based vaccine. Today, this partnership is helping accelerate the development of individualized cancer treatments.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19